Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond

References

• Mancilla VJ, Peeri NC, Silzer T, et al. Understanding the interplay between health disparities and Epigenomics. Front Genet. 2020;11:903. doi: 10.3389/fgene.2020.00903
   PubMed Web of Science ®Google Scholar
• Kumar M, Sarma DK, Shubham S, et al. Environmental endocrine-disrupting chemical exposure: role in non-communicable diseases. Front Public Health. 2020;8:553850. doi: 10.3389/fpubh.2020.553850
   PubMed Web of Science ®Google Scholar
• Varadhan A, Stephan K, Gupta R, et al. Growing role of SGLT2i in heart failure: evidence from clinical trials. Expert Rev Clin Pharmacol. 2022;15(2):147–159. doi: 10.1080/17512433.2022.2051480
   PubMed Web of Science ®Google Scholar
• Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabet Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Saudek CD, Herman WH, Sacks DB, et al. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab. 2008;93(7):2447–2453. doi: 10.1210/jc.2007-2174
   PubMed Web of Science ®Google Scholar
• Borch-Johnsen K, Colagiuri S. Diagnosing diabetes–time for a change? Diabetologia. 2009;52(11):2247–2250. doi: 10.1007/s00125-009-1526-1
   PubMed Web of Science ®Google Scholar
• International Expert C. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327–1334. doi: 10.2337/dc09-9033
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Herman WH. The cost of diabetes care-an elephant in the room. Diabetes Care. 2018;41(5):929–932. doi: 10.2337/dci18-0012
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice C. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144–S174. doi: 10.2337/dc22-S010
   PubMedGoogle Scholar
• American Diabetes Association Professional Practice C. Erratum. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl. 1):S144–S174. doi: 10.2337/dc22-S010
   PubMedGoogle Scholar
• Relimpio F, Pumar A, Losada F, et al. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial. Diabet Med. 1998;15(12):997–1002. doi: 10.1002/(SICI)1096-9136(1998120)15:12<997:AID-DIA716>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. doi: 10.1007/s00125-017-4336-x
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice C, American Diabetes Association Professional Practice C, Draznin B, Aroda VR, et al. 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S60–S82.
   PubMedGoogle Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi: 10.2337/dci19-0066
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810–7. doi: 10.1210/jc.2008-1518
   PubMed Web of Science ®Google Scholar
• Levin PA, Nguyen H, Wittbrodt ET, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes. 2017;10:123–139. doi: 10.2147/DMSO.S130834
   PubMed Web of Science ®Google Scholar
• Singh S, Wright EE Jr., Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Obes Metab. 2017;19(2):228–238. doi: 10.1111/dom.12805
   PubMed Web of Science ®Google Scholar
• Abd El Aziz MS, Kahle M, Meier JJ, et al. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017;19(2):216–227. doi: 10.1111/dom.12804
   PubMed Web of Science ®Google Scholar
• Modi P. Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. Curr drug Discov Technol. 2007;4(1):39–47. doi: 10.2174/157016307781115476
   Google Scholar
• Mullard A. Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics. Nat Rev Drug Discov. 2022;21(7):480. doi: 10.1038/d41573-022-00094-2
   Web of Science ®Google Scholar
• Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. doi: 10.1073/pnas.2116506119
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diab Obes Metab. 2020;22(6):938–946. doi: 10.1111/dom.13979
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–2193. doi: 10.1016/S0140-6736(18)32260-8
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study of tirzepatide (LY3298176) compared with dulaglutide on Major cardiovascular events in participants with type 2 diabetes (SURPASS-CVOT). 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04255433
   Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. doi: 10.1056/NEJMoa2206038
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study of tirzepatide in participants with impaired liver function. 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT03940742
   Google Scholar
• Moura FA, Scirica BM, Ruff CT. Tirzepatide for diabetes: on track to SURPASS current therapy. Nat Med. 2022;28(3):450–451. doi: 10.1038/s41591-022-01733-2
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study of tirzepatide (LY3298176) in participants with type 2 diabetes not controlled with diet and exercise alone (SURPASS-1). 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03954834
   Google Scholar
• Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55. doi: 10.1016/S0140-6736(21)01324-6
   PubMed Web of Science ®Google Scholar
• Tan B, Pan XH, Chew HSJ, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). 2023;47(8):677–685. doi: 10.1038/s41366-023-01321-5
   PubMed Web of Science ®Google Scholar
• Ludvik B, Giorgino F, Jodar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–598. doi: 10.1016/S0140-6736(21)01443-4
   PubMed Web of Science ®Google Scholar
• Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–1824. doi: 10.1016/S0140-6736(21)02188-7
   PubMed Web of Science ®Google Scholar
• Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–545. doi: 10.1001/jama.2022.0078
   PubMed Web of Science ®Google Scholar
• Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023;8(2):179–191. doi: 10.1016/S2468-1253(22)00338-7
   PubMed Web of Science ®Google Scholar
• Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623–633. doi: 10.1016/S2213-8587(22)00188-7
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Chin R, Ozeki A, et al. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):634–644. doi: 10.1016/S2213-8587(22)00187-5
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study of tirzepatide (LY3298176) in participants with type 2 diabetes who have obesity or are overweight (SURMOUNT-2). 2023. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04657003
   Google Scholar
• Clinicaltrials.gov. A study of tirzepatide compared with intensified conventional care in adult participants with type 2 diabetes (SURPASS-EARLY). 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT05433584
   Google Scholar
• Clinicaltrials.gov. A study of tirzepatide (LY3298176) in participants after a lifestyle weight loss program (SURMOUNT-3). 2023. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04657016
   Google Scholar
• Clinicaltrials.gov. A study of tirzepatide (LY3298176) in participants with obesity or overweight for the maintenance of weight loss (SURMOUNT-4). 2023. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04660643
   Google Scholar
• Soldevila B, Puig-Domingo M. Safety and tolerability of GLP-1 receptor agonists. Med Clin. 2014;143(Suppl 2):35–40. doi: 10.1016/S0025-7753(14)70107-1
   Google Scholar
• Marathe CS, Rayner CK, Wu T, et al. Gastrointestinal disorders in diabetes. In: editors, Feingold K, Anawalt B, Blackman M, Boyce A, Chrousos G, and Corpas E, et al., editors. Endotext. South Dartmouth (MA); 2000. https://www.ncbi.nlm.nih.gov/books/NBK553219/
   Google Scholar
• Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide Once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15. doi: 10.1056/NEJMoa2107519
   PubMed Web of Science ®Google Scholar
• Mishra R, Raj R, Elshimy G, et al. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023;7(4):bvad016. doi: 10.1210/jendso/bvad016
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Hoog M, Mody R, et al. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diab Obes Metab. 2023;25(5):1292–1300.
   PubMed Web of Science ®Google Scholar
• Zhang X, McAdam Marx C. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States. J Manag Care Spec Pharm. 2023;29(3):276–284.
   PubMed Web of Science ®Google Scholar
• Azuri J, Hammerman A, Aboalhasan E, et al. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: a value for money analysis. Diab Obes Metab. 2022;146(Suppl_1). doi: 10.1161/circ.146.suppl_1.15300
   Google Scholar